Metropolitan Life Insurance Co. NY lifted its holdings in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 456.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,283 shares of the biotechnology company’s stock after buying an additional 10,895 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Five Prime Therapeutics were worth $124,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Quantamental Technologies LLC purchased a new stake in shares of Five Prime Therapeutics in the 4th quarter worth about $58,000. Virtu Financial LLC bought a new position in Five Prime Therapeutics in the 4th quarter worth about $113,000. Dynamic Technology Lab Private Ltd bought a new position in Five Prime Therapeutics in the 3rd quarter worth about $190,000. Jefferies Group LLC bought a new position in Five Prime Therapeutics in the 3rd quarter worth about $191,000. Finally, BlueMountain Capital Management LLC boosted its stake in Five Prime Therapeutics by 398.9% in the 3rd quarter. BlueMountain Capital Management LLC now owns 14,766 shares of the biotechnology company’s stock worth $206,000 after purchasing an additional 11,806 shares in the last quarter. 86.62% of the stock is currently owned by hedge funds and other institutional investors.
FPRX opened at $11.91 on Friday. Five Prime Therapeutics Inc has a 52-week low of $7.84 and a 52-week high of $19.70.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative net margin of 281.64% and a negative return on equity of 44.55%. As a group, equities research analysts expect that Five Prime Therapeutics Inc will post -3.99 earnings per share for the current year.
A number of equities analysts recently issued reports on FPRX shares. Wedbush upgraded shares of Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Thursday, January 17th. ValuEngine upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 20th. Guggenheim started coverage on shares of Five Prime Therapeutics in a research note on Friday, April 12th. They issued a “buy” rating and a $24.00 price target on the stock. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Monday, January 21st. Finally, BidaskClub upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 22nd. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Five Prime Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $24.25.
TRADEMARK VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Acquires 10,895 Shares of Five Prime Therapeutics Inc (FPRX)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2019/04/21/metropolitan-life-insurance-co-ny-acquires-10895-shares-of-five-prime-therapeutics-inc-fprx.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Read More: How to identify percentage decliners
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.